JP2022087185A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022087185A5 JP2022087185A5 JP2022062862A JP2022062862A JP2022087185A5 JP 2022087185 A5 JP2022087185 A5 JP 2022087185A5 JP 2022062862 A JP2022062862 A JP 2022062862A JP 2022062862 A JP2022062862 A JP 2022062862A JP 2022087185 A5 JP2022087185 A5 JP 2022087185A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- tim
- binding agent
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762444354P | 2017-01-09 | 2017-01-09 | |
| US62/444,354 | 2017-01-09 | ||
| US201762582272P | 2017-11-06 | 2017-11-06 | |
| US62/582,272 | 2017-11-06 | ||
| PCT/US2018/013021 WO2018129553A1 (en) | 2017-01-09 | 2018-01-09 | Methods of treating cancer with anti-tim-3 antibodies |
| JP2019537099A JP7118073B2 (ja) | 2017-01-09 | 2018-01-09 | 抗ｔｉｍ－３抗体を用いてがんを処置する方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019537099A Division JP7118073B2 (ja) | 2017-01-09 | 2018-01-09 | 抗ｔｉｍ－３抗体を用いてがんを処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022087185A JP2022087185A (ja) | 2022-06-09 |
| JP2022087185A5 true JP2022087185A5 (https=) | 2022-09-07 |
| JP7472190B2 JP7472190B2 (ja) | 2024-04-22 |
Family
ID=61163782
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019537099A Active JP7118073B2 (ja) | 2017-01-09 | 2018-01-09 | 抗ｔｉｍ－３抗体を用いてがんを処置する方法 |
| JP2022062862A Active JP7472190B2 (ja) | 2017-01-09 | 2022-04-05 | 抗ｔｉｍ－３抗体を用いてがんを処置する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019537099A Active JP7118073B2 (ja) | 2017-01-09 | 2018-01-09 | 抗ｔｉｍ－３抗体を用いてがんを処置する方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11926665B2 (https=) |
| EP (1) | EP3565594A1 (https=) |
| JP (2) | JP7118073B2 (https=) |
| KR (1) | KR102671283B1 (https=) |
| CN (1) | CN110382000A (https=) |
| AU (1) | AU2018205401B2 (https=) |
| BR (1) | BR112019014169A2 (https=) |
| CA (1) | CA3049536A1 (https=) |
| IL (1) | IL267803A (https=) |
| MA (1) | MA47206A (https=) |
| MX (1) | MX2019008208A (https=) |
| SG (1) | SG10201913083SA (https=) |
| TW (2) | TWI793094B (https=) |
| WO (1) | WO2018129553A1 (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3274370T (pt) | 2015-03-23 | 2020-01-30 | Bayer Pharma AG | Anticorpos anti-ceacam6 e utilizações dos mesmos |
| EA201792184A1 (ru) | 2015-04-01 | 2018-04-30 | Анаптисбайо, Инк. | Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3) |
| SG10201912663YA (en) | 2016-10-11 | 2020-03-30 | Agenus Inc | Anti-lag-3 antibodies and methods of use thereof |
| SG11201903867YA (en) * | 2016-11-01 | 2019-05-30 | Anaptysbio Inc | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| CA3041684C (en) * | 2016-11-01 | 2023-09-26 | Anaptysbio, Inc. | Antibodies directed against programmed death- 1 (pd-1) |
| PT3565844T (pt) | 2017-01-09 | 2023-05-02 | Tesaro Inc | Métodos de tratamento de cancro com anticorpos anti-pd-1 |
| MX2019008208A (es) | 2017-01-09 | 2019-12-11 | Tesaro Inc | Métodos para tratar el cáncer con anticuerpos anti-tim-3. |
| TWI879716B (zh) * | 2017-05-09 | 2025-04-11 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| AU2018270112A1 (en) | 2017-05-18 | 2019-12-12 | Tesaro, Inc. | Combination therapies for treating cancer |
| KR20250016494A (ko) | 2017-09-26 | 2025-02-03 | 테사로, 인코포레이티드 | 니라파립 제제 |
| EP3697442A4 (en) | 2017-09-30 | 2021-07-07 | Tesaro, Inc. | COMBINATION THERAPIES FOR TREATMENT OF CANCER |
| SG11202002499TA (en) | 2017-10-06 | 2020-04-29 | Tesaro Inc | Combination therapies and uses thereof |
| US20210363242A1 (en) * | 2018-01-16 | 2021-11-25 | Bristol-Myers Squibb Company | Methods of treating cancer with antibodies against tim3 |
| WO2020072797A1 (en) | 2018-10-03 | 2020-04-09 | Tesaro, Inc. | Niraparib salts |
| US20210347758A1 (en) | 2018-10-03 | 2021-11-11 | Tesaro, Inc. | Crystalline Forms of Niraparib Freebase |
| CN113272017A (zh) * | 2018-11-01 | 2021-08-17 | 默克专利有限公司 | 抗tim-3抗体 |
| JP7521163B2 (ja) | 2018-12-19 | 2024-07-24 | ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ | 抗ｃｅａｃａｍ６及びｔｉｍ３抗体の医薬組み合わせ |
| CN113614109A (zh) | 2018-12-21 | 2021-11-05 | Ose免疫疗法公司 | 双功能抗pd-1/il-7分子 |
| CA3126133A1 (en) * | 2019-01-11 | 2020-07-16 | Eli Lilly And Company | Tim-3 antibodies and combinations with other checkpoint inhibitors for the treatment of cancer |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| AU2020406083A1 (en) | 2019-12-17 | 2022-06-16 | Boehringer Ingelheim International Gmbh | Bifunctional molecules comprising an IL-7 variant |
| AU2021257570A1 (en) | 2020-04-14 | 2022-11-03 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer |
| AU2021256652A1 (en) | 2020-04-14 | 2022-11-03 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer involving anti-ICOS and anti-PD1 antibodies, optionally further involving anti-tim3 antibodies |
| WO2022006091A1 (en) * | 2020-06-29 | 2022-01-06 | Anovent Pharmaceutical (U.S.), Llc | Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation |
| WO2022148781A1 (en) | 2021-01-05 | 2022-07-14 | Institut Curie | Combination of mcoln activators and immune checkpoint inhibitors |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| AU2022253351A1 (en) | 2021-04-09 | 2023-10-12 | Boehringer Ingelheim International Gmbh | New scaffold for bifunctional molecules with improved properties |
| CN117120091A (zh) * | 2021-04-13 | 2023-11-24 | 免疫医疗有限责任公司 | 靶向pd-1和tim-3的双特异性抗体 |
| CN117377692A (zh) | 2021-04-23 | 2024-01-09 | 苏州逻晟生物医药有限公司 | Tim-3-靶向抗体及其用途 |
| US11970548B2 (en) * | 2021-08-27 | 2024-04-30 | Innovative Cellular Therapeutics Holdings, Ltd. | Nanobody target GCC and uses in chimeric antigen receptor cell therapy |
| US20240368280A1 (en) | 2021-09-02 | 2024-11-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Anti-cecam6 antibodies with reduced side-effects |
| US20230391873A1 (en) * | 2022-06-02 | 2023-12-07 | Memorial Sloan-Kettering Cancer Center | Methods for treating mismatch repair deficient locally advanced rectal cancer using dostarlimab |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| US20250034255A1 (en) * | 2023-03-08 | 2025-01-30 | Incyte Corporation | Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer |
| AU2024254671A1 (en) | 2023-03-30 | 2025-10-02 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| CN121358499A (zh) | 2023-03-30 | 2026-01-16 | Ose免疫疗法 | 靶向活化的免疫细胞以表达免疫细胞增强分子的基于脂质的纳米粒及其用途 |
| WO2025014933A1 (en) * | 2023-07-10 | 2025-01-16 | Northwestern University | Targeting tim-3 in mapk-driven glioma |
| WO2025242836A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2026068705A1 (en) | 2024-09-26 | 2026-04-02 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4828981A (en) | 1983-08-24 | 1989-05-09 | Synbiotics Corporation | Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| CA2096222C (en) | 1990-11-13 | 1998-12-29 | Stephen D. Lupton | Bifunctional selectable fusion genes |
| WO1994028143A1 (en) | 1993-05-21 | 1994-12-08 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| WO2001057219A2 (en) | 2000-02-02 | 2001-08-09 | Schering Corporation | Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods |
| FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
| US20030103985A1 (en) | 2001-05-18 | 2003-06-05 | Boehringer Ingelheim International Gmbh | Cytotoxic CD44 antibody immunoconjugates |
| CA2467633C (en) | 2001-12-03 | 2012-03-27 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
| AU2003303082B2 (en) | 2002-01-30 | 2009-07-02 | Dana-Farber Cancer Institute, Inc. | Compositions and methods related to TIM-3, a Th1-specific cell surface molecule |
| US20030229910A1 (en) | 2002-04-17 | 2003-12-11 | Richard Metz | Short fragment homologous replacement to provide BSE resistant cattle |
| GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
| US20060134105A1 (en) | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| US7824681B2 (en) | 2005-08-16 | 2010-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Human monoclonal antibodies that specifically bind IGF-II |
| LT2468770T (lt) | 2006-07-14 | 2018-05-25 | Ac Immune S.A. | Humanizuotas antikūnas prieš beta amiloidą |
| NZ574188A (en) | 2006-07-14 | 2012-05-25 | Ac Immune Sa | Humanized antibody against amyloid beta |
| MX2009002456A (es) | 2006-09-08 | 2009-03-20 | Amgen Inc | Variantes de la familia il-1. |
| AR064777A1 (es) | 2007-01-10 | 2009-04-22 | Inst Di Reserche D Biolog Mole | Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp) |
| BRPI0807952A2 (pt) | 2007-02-20 | 2014-06-10 | Anaptysbio Inc | Sistemas de hipermutação somática |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| JP5989965B2 (ja) | 2008-01-08 | 2016-09-07 | メルク シャープ エンド ドーム リミテッド | ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| WO2009129247A2 (en) | 2008-04-14 | 2009-10-22 | Innovative Targeting Solutions Inc. | Sequence diversity generation in immunoglobulins |
| US20110159011A1 (en) | 2008-08-28 | 2011-06-30 | Wyeth Llc | Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases |
| WO2011155607A1 (ja) | 2010-06-11 | 2011-12-15 | 協和発酵キリン株式会社 | 抗ｔｉｍ－３抗体 |
| JP2013532153A (ja) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体 |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| WO2013016220A1 (en) | 2011-07-22 | 2013-01-31 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
| EP2748197A2 (en) | 2011-08-26 | 2014-07-02 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
| KR102038310B1 (ko) | 2011-11-16 | 2019-11-01 | 베링거 인겔하임 인터내셔날 게엠베하 | 항 ｉｌ-36ｒ 항체 |
| ES2668104T3 (es) | 2011-12-28 | 2018-05-16 | Immunoqure Ag | Procedimiento de aislamiento de anticuerpos humanos |
| EP2861617A1 (en) | 2012-06-15 | 2015-04-22 | Pfizer Inc. | Improved antagonist antibodies against gdf-8 and uses therefor |
| JP6162319B2 (ja) | 2013-03-12 | 2017-07-12 | デシミューン セラピューティクス，インコーポレイテッド | ヒト化抗ｎ２抗体 |
| JP6586016B2 (ja) | 2013-03-15 | 2019-10-02 | ノヴォ ノルディスク アー／エス | 組織因子系凝固インヒビター上の２つのエピトープに特異的に結合することが可能な抗体 |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| EP3099717B1 (en) * | 2014-01-31 | 2019-03-27 | Novartis AG | Antibody molecules to tim-3 and uses thereof |
| US20150259420A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| GB201419094D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
| PT3215532T (pt) | 2014-11-06 | 2019-12-18 | Hoffmann La Roche | Anticorpos anti-tim3 e métodos de utilização |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| EA201792184A1 (ru) | 2015-04-01 | 2018-04-30 | Анаптисбайо, Инк. | Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3) |
| DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
| EP3370768B9 (en) | 2015-11-03 | 2022-03-16 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
| AR108377A1 (es) | 2016-05-06 | 2018-08-15 | Medimmune Llc | Proteínas de unión biespecíficas y sus usos |
| KR20230042136A (ko) | 2016-06-29 | 2023-03-27 | 테사로, 인코포레이티드 | 난소암의 치료 방법 |
| US11203637B2 (en) | 2016-08-26 | 2021-12-21 | Beigene, Ltd. | Anti-Tim-3 antibodies and use thereof |
| SG11201903867YA (en) | 2016-11-01 | 2019-05-30 | Anaptysbio Inc | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| MX2019008208A (es) | 2017-01-09 | 2019-12-11 | Tesaro Inc | Métodos para tratar el cáncer con anticuerpos anti-tim-3. |
| AR111651A1 (es) * | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
-
2018
- 2018-01-09 MX MX2019008208A patent/MX2019008208A/es unknown
- 2018-01-09 TW TW107100821A patent/TWI793094B/zh active
- 2018-01-09 SG SG10201913083SA patent/SG10201913083SA/en unknown
- 2018-01-09 CA CA3049536A patent/CA3049536A1/en active Pending
- 2018-01-09 TW TW112102836A patent/TWI841209B/zh active
- 2018-01-09 US US16/476,534 patent/US11926665B2/en active Active
- 2018-01-09 AU AU2018205401A patent/AU2018205401B2/en active Active
- 2018-01-09 CN CN201880016126.4A patent/CN110382000A/zh active Pending
- 2018-01-09 JP JP2019537099A patent/JP7118073B2/ja active Active
- 2018-01-09 EP EP18703388.1A patent/EP3565594A1/en active Pending
- 2018-01-09 KR KR1020197023158A patent/KR102671283B1/ko active Active
- 2018-01-09 MA MA047206A patent/MA47206A/fr unknown
- 2018-01-09 BR BR112019014169-3A patent/BR112019014169A2/pt unknown
- 2018-01-09 WO PCT/US2018/013021 patent/WO2018129553A1/en not_active Ceased
-
2019
- 2019-07-02 IL IL267803A patent/IL267803A/en unknown
-
2022
- 2022-04-05 JP JP2022062862A patent/JP7472190B2/ja active Active
-
2024
- 2024-02-02 US US18/430,835 patent/US20240301057A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022087185A5 (https=) | ||
| JP2020504141A5 (https=) | ||
| JP2020503364A5 (https=) | ||
| Wang et al. | The state of the art of bispecific antibodies for treating human malignancies | |
| JP2023027199A5 (https=) | ||
| JP2021155431A5 (https=) | ||
| JP2022050618A5 (https=) | ||
| Chen et al. | A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy | |
| JP2020508317A5 (https=) | ||
| JP2017506067A5 (https=) | ||
| RU2018100424A (ru) | Комбинированная терапия для лечения злокачественной опухоли | |
| JP2021513541A5 (https=) | ||
| HRP20171758T1 (hr) | Kombinacija dr5 agonista i anti-pd-1 antagonista i načini primjene | |
| JP6241932B2 (ja) | 腫瘍性疾患のための治療 | |
| CN111278861A (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| JP2008508858A5 (https=) | ||
| JPWO2020047389A5 (https=) | ||
| JP7809635B2 (ja) | Ｌａｇ－３アンタゴニスト治療のための定量的空間プロファイリング | |
| Pan et al. | Characterization of a novel bispecific antibody targeting tissue factor-positive tumors with T cell engagement | |
| JPWO2019160751A5 (https=) | ||
| JPWO2023288241A5 (https=) | ||
| CN109663130A (zh) | Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JPWO2023151693A5 (https=) | ||
| CN120731228A (zh) | 肺癌的组合疗法 | |
| JPWO2021133653A5 (https=) |